Ariana Pelosci

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.

HER2DX demonstrated the ability to select patients who are more likely to achieve disease control with anti-HER2 standard of care in the CLEOPATRA trial.

BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.

Second-line fruquintinib plus paclitaxel did not sustain sufficient efficacy for patients with advanced gastric or GEJ adenocarcinoma to support approval in China.

Trials assessing NSCLC and cutaneous squamous cell carcinoma were discontinued due to no benefit observed or improvement noted with the primary end points.

A watch-and-wait method was implemented when vitamin D was given prior to treatment for chronic lymphocytic leukemia.

A PDUFA date has been set for February 28, 2025, for the potential approval of mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Brentuximab vedotin plus chemotherapy significantly improved HRQOL in both pediatric and young adult patients with high-risk Hodgkin lymphoma.

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.

Results from the phase 3 AEGEAN trial led to the approval of neoadjuvant and adjuvant durvalumab for patients with resectable NSCLC.

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

“Sometimes you have to be a little more assertive and a little louder, and you have to step up to the front,” Julie M. Vose, MD, MBA, said.

Findings from the PREVENT study show that bioimpedance spectroscopy use may reduce progression to chronic lymphedema compared with tape measure use.

Various immunotherapy/TKI regimens were observed to determine the impact on survival in patients with metastatic renal cell carcinoma.

Collecting and analyzing patient data through an AI tool may help with more accurately predicting outcomes and personalizing treatment.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.